Thomas Andrew J, Mace Jess C, Ramakrishnan Vijay R, Alt Jeremiah A, Mattos Jose L, Schlosser Rodney J, Soler Zachary M, Smith Timothy L
Division of Rhinology and Sinus/Skull Base Surgery, Department of Otolaryngology-Head and Neck Surgery, Oregon Health Center, Oregon Health & Science University, Portland, OR.
Department of Otorhinolaryngology, Ochsner Clinic Foundation, New Orleans, LA.
Int Forum Allergy Rhinol. 2020 May;10(5):656-664. doi: 10.1002/alr.22532. Epub 2020 Feb 3.
Patients with chronic rhinosinusitis (CRS) commonly experience both reduced quality of life (QOL) and olfactory dysfunction (OD). Literature on the impacts of appropriate medical therapy (AMT) for CRS on QOL and OD is limited, and the focused design of these studies may limit their applicability to usual clinical practice.
Adults with symptomatic CRS were prospectively enrolled (November 2016 to October 2018) into an observational, multi-institutional study. Individualized AMT was initiated using standard practice according to evidence-based guidelines. Endoscopy examination (Lund-Kennedy), olfactory function (Sniffin' Sticks) testing, and QOL survey responses (22-item Sino-Nasal Outcome Test [SNOT-22], Questionnaire of Olfactory Disorders-Negative Statements [QOD-NS]) were obtained at enrollment and follow-up.
Baseline measures demonstrated heterogeneity of QOL and OD. After an average of 7.8 weeks, within-subject median SNOT-22 total improved by 39.5% (n = 39, p < 0.001) relative to baseline, including 50% (p = 0.014) improvement for item #21, "Sense of smell/taste." QOD-NS improvement was also statistically significant (p = 0.044). Sniffin' Sticks score relative improvement of 10.9% (n = 33, p = 0.109) was not statistically significant and lacked correlation with SNOT-22 total scores (R = -0.247, p = 0.165) or QOD-NS total scores (R = -0.016, p = 0.930), but correlated moderately with endoscopy score (R = -0.436, p = 0.018).
Participants with varied impacts of CRS, treated with individualized short-term AMT, demonstrated significant improvements in CRS- and olfactory-specific QOL measures, without corresponding improvement in clinically measured olfactory function. Olfactory function changes moderately correlated with endoscopy score changes, but lacked an association with QOL measurements.
慢性鼻-鼻窦炎(CRS)患者通常生活质量(QOL)下降且存在嗅觉功能障碍(OD)。关于CRS的适当药物治疗(AMT)对QOL和OD影响的文献有限,而且这些研究的针对性设计可能会限制其在日常临床实践中的适用性。
有症状的CRS成年患者前瞻性纳入(2016年11月至2018年10月)一项观察性多机构研究。根据循证指南采用标准做法启动个体化AMT。在入组和随访时进行内镜检查(Lund-Kennedy)、嗅觉功能(嗅棒)测试以及QOL调查应答(22项鼻-鼻窦结局测试[SNOT-22]、嗅觉障碍问卷-否定陈述[QOD-NS])。
基线测量显示QOL和OD存在异质性。平均7.8周后,受试者内SNOT-22总分中位数相对于基线改善了39.5%(n = 39,p < 0.001),包括第21项“嗅觉/味觉”改善了50%(p = 0.014)。QOD-NS的改善也具有统计学意义(p = 0.044)。嗅棒评分相对改善10.9%(n = 33,p = 0.109)无统计学意义,且与SNOT-22总分(R = -0.247,p = 0.165)或QOD-NS总分(R = -0.016,p = 0.930)缺乏相关性,但与内镜评分中度相关(R = -0.436,p = 0.018)。
接受个体化短期AMT治疗的CRS影响各异的参与者在CRS及嗅觉特异性QOL指标上有显著改善,但临床测量的嗅觉功能无相应改善。嗅觉功能变化与内镜评分变化中度相关,但与QOL测量缺乏关联。